Proteins, I.e., More Than 100 Amino Acid Residues Patents (Class 530/350)
  • Patent number: 9766201
    Abstract: Various devices, systems and methods for determining a parameter of and/or detecting chemical and biological substances in bodily fluid are described herein. A device or system may include a substrate. An active sensor having an electrical characteristic and/or a control sensor may be disposed on the substrate. In certain variations, a differential between a first signal from the active sensor, and a second signal from the control sensor may be used to determine a parameter of the chemical or biological substance in the sample of bodily fluid.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: September 19, 2017
    Assignee: Avails Medical, Inc.
    Inventors: Meike Herget, Oren S. Knopfmacher
  • Patent number: 9764012
    Abstract: Nanoparticle-based vaccines, compositions, kits and methods are used for the effective delivery of one or more antigens in vivo for vaccination and antibody (e.g., monoclonal antibody) production, and for the effective delivery of peptides, proteins, siRNA, RNA or DNA to PAPCs or MHC class II positive cells (e.g. tumor cells). Antigens may be, for example, DNA that results in expression of the gene of interest and induction of a robust and specific immune response to the expressed protein in a subject (e.g., mammal). Antigens may also be immunogenic peptides or polypeptides that are processed and presented. In one embodiment, a nanoparticle-based method to deliver antigens in vivo as described herein includes injection of a vaccine composed of a DNA encoding at least one antigen, or at least one antigenic peptide or polypeptide conjugated to a charged dendrimer (e.g., PADRE-derivatized dendrimer) that is also conjugated to a T helper epitope (e.g., PADRE).
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: September 19, 2017
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Pirouz M. Daftarian, Paolo Serafini, Vance Paul Lemmon, Angel Kaifer, Victor Perez, Wei Li, Bonnie Beth Blomberg
  • Patent number: 9765125
    Abstract: Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromised patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in Streptococcus pneumoniae that contain fusion proteins. The antigens may be used therapeutically or prophylactically.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: September 19, 2017
    Assignees: Genocea Biosciences, Inc., Children's Medical Center Corporation
    Inventors: Jessica Flechtner, Richard Malley
  • Patent number: 9765134
    Abstract: The marginal zone (MZ) and B1 subsets of B cells, which differ from conventional follicular (FO) B cells both developmentally and functionally, are involved in early responses to infectious pathogens and the production of self-reactive antibodies. A novel gene, mzb1, is expressed at high levels in MZ and B1 B cells but at low level, if at all, in FO B cells. MZB1 is involved in the regulation of proliferation, BCR-mediated signal transduction, and antibody production in B cells. Inhibitors, activators and enhancers of MZB1 expression or activity can be used as immune modulators for research and therapeutic purposes.
    Type: Grant
    Filed: January 14, 2013
    Date of Patent: September 19, 2017
    Assignee: Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.
    Inventors: Rudolf Grosschedl, Henrik Flach, Sola Kim, Marlena Duchniewicz, Bernadette Schreiner, Marc Rosenbaum
  • Patent number: 9757587
    Abstract: Stimulation of target cells using light, e.g., in vivo or in vitro, is implemented using a variety of methods and devices. One example involves a vector for delivering a light-activated NpHR-based molecule comprising a nucleic acid sequence that codes for light-activated NpHR-based molecule and a promoter. Either a high expression of the molecule manifests a toxicity level that is less than about 75%, or the light-activated NpHR-based proteins are expressed using at least two NpHR-based molecular variants. Each of the variants characterized in being useful for expressing a light-activated NpHR-based molecule that responds to light by producing an inhibitory current to dissuade depolarization of the neuron. Other aspects and embodiments are directed to systems, methods, kits, compositions of matter and molecules for ion pumps or for controlling inhibitory currents in a cell (e.g., in in vivo and in vitro environments).
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: September 12, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl Deisseroth, Feng Zhang, Viviana Gradinaru
  • Patent number: 9758584
    Abstract: The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: September 12, 2017
    Assignee: Ablynx N.V.
    Inventors: Francis Descamps, Maria Gonzalez, Pascal Gerard Merchiers, Catelijne Stortelers, Peter Vanlandschoot, Philippe Van Rompaey, Martine Smit, Regorius Leurs, David Andre Baptiste Maussang-Detaille
  • Patent number: 9758802
    Abstract: The invention provides a method of degrading or hydrolyzing a polysaccharide, preferably cellulose or chitin, comprising contacting said polysaccharide with one or more oxidohydrolytic enzymes, preferably a CBM33 family protein (preferably CBP21) or a GH61 family protein, wherein said degradation or hydrolysis is carried out in the presence of at least one reducing agent and at least one divalent metal ion. A method of producing an organic substance comprising said method is also provided.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: September 12, 2017
    Assignees: NOVOZYMES A/S, Novozymes, Inc.
    Inventors: Gustav Vaaje-Kolstad, Bjorge Westereng, Vincent G. H. Eijsink, Svein J. Horn, Morten Sorliie, Zarah Forsberg
  • Patent number: 9758832
    Abstract: The present invention provides compositions and methods for research, diagnostic, drug screening, and therapeutic applications related to paroxysmal dystonic choreoathetosis and related conditions. In particular, the present invention provides mutations in the myofibrillogenesis regulator 1 (MR-1) gene associated with such conditions.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: September 12, 2017
    Assignee: The Regents of the University of Michigan
    Inventors: John K. Fink, Shirley Rainier
  • Patent number: 9732143
    Abstract: Novel materials and methods useful for expressing heterologous proteins in prokaryotic cells are provided, including prokaryotic cells expressing FkpA and/or Skp.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: August 15, 2017
    Assignee: XOMA TECHNOLOGY LTD.
    Inventors: Raphael D. Levy, Chung-Leung Chan, Kiranjit K. Ahluwalia, Toshihiko Takeuchi
  • Patent number: 9732127
    Abstract: The invention relates to intracellular lipid binding proteins that bind retinoids and/or dye ligands and that are modified to transmit or emit light at a variety of different wavelengths.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: August 15, 2017
    Assignee: Board of Trustees of Michigan State University
    Inventors: Babak Borhan, James Geiger, Wenjing Wang, Chrysoula Vasileiou, Kin Sing Lee, Tetyana Berbasova
  • Patent number: 9724337
    Abstract: Compositions, methods, and combination therapies for the treatment of cancers, including lymphomas, leukemias, melanomas, lung cancer, and metastatic disease, are provided. Specifically, compositions comprising ligands to Pgrmc1 are disclosed for use in treating and inhibiting tumor growth and progression and inhibition of metastases. The compositions and methods using these ligands can be used alone or in combination with other reagents and cancer treatment modalities.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: August 8, 2017
    Assignee: University of Kentucky Research Foundation
    Inventor: Rolf Joseph Craven
  • Patent number: 9724389
    Abstract: A system for multiphasic delivery of at least one growth factor at a treatment site comprises a delivery vehicle for releasing at least one growth factor in an initial release profile and a carrier for releasing at least one growth factor in a sustained release profile. The initial release profile releases at least one growth factor over a period of hours to days, wherein the growth factor is released in a large amount initially, with the remainder being released in progressively lower amounts. The sustained release profile releases at least one growth factor over a period of days to weeks, wherein the growth factor is released at a generally constant amount over such period. The system of the invention is particularly suited for applications on bioimplants. The invention also comprises methods and kits for multiphasic delivery of at least one growth factor.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: August 8, 2017
    Assignee: INDUCE BIOLOGICS, INC.
    Inventors: Sean A. F. Peel, Cameron M. L. Clokie
  • Patent number: 9708408
    Abstract: The present invention relates to methods of treating or preventing cancer and other diseases using molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds an Fc?R that activates a cellular effector (“Fc?RActivating,” such as Fc?RIIA or Fc?RIIIA) and an Fc?R that inhibits a cellular effector (“Fc?RInhibiting,” such as Fc?RIIA) with an altered Ratio of Affinities relative to the respective binding affinities of such Fc?R for the Fc region of the wild-type immunoglobulin. The methods of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where either an enhanced efficacy of effector cell function mediated by Fc?R is desired (e.g.
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: July 18, 2017
    Assignee: MacroGenics, Inc.
    Inventors: Jeffrey B. Stavenhagen, Scott Koenig
  • Patent number: 9707535
    Abstract: The present disclosure generally pertains to systems and methods for the chemical synthesis of micro-quantities of oligonucleotides or other chemical molecules. The system includes a reusable glass micro-reactor containing a paramagnetic solid support, a magnet, an electronic drive controller and an optical spectroscopy system capable of driving a plurality individual reactors. The system utilizes the electroosmotic movement of reactants through microfluidic channels. Spectrophotometric monitoring of the reaction products allows for the real-time determination of synthesis yield.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: July 18, 2017
    Assignee: The Board of Trustees of the University of Alabama, for and on behalf of the University of Alabama in Huntsville
    Inventors: Lance Amate Larka, John D. Williams, Randy Gaillard
  • Patent number: 9701754
    Abstract: The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: July 11, 2017
    Assignee: City of Hope
    Inventors: Anna M. Wu, John E. Shively, Andrew A. Raubitschek, Mark A. Sherman, Tove Olafsen
  • Patent number: 9701749
    Abstract: Provided is a prophylactic, symptom progress-suppressive, and/or therapeutic agent for an autoimmune disease. The agent lowers the risk of infections and reduces the burden of administration to patients. The prophylactic, symptom progress-suppressive, and/or therapeutic agent includes a PD-1 agonist as an active ingredient and is administered (a) 1 to 10 times within one month from the first administration, (b) in a total PD-1 agonist dose of 20 to 1250 ?g/kg, and (c) without requiring administration for at least 3 months after the last administration.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: July 11, 2017
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shiro Shibayama, Masamichi Imai
  • Patent number: 9695250
    Abstract: The present disclosure relates to a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding domain specifically binding to human CEA, where the second binding domain comprises at least a part of the CDR-H3 or the complete CDR-H3 of murine monoclonal antibody A5B7, a pharmaceutical composition comprising the bispecific single chain antibody, and methods for the treatment of an epithelial tumor in a human with the pharmaceutical compositions containing the bispecific single chain antibody. Furthermore, processes for the production of the pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CEA antigen are disclosed.
    Type: Grant
    Filed: January 14, 2013
    Date of Patent: July 4, 2017
    Assignee: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Ralf Lutterbüse, Petra Fluhr, Evelyne Schaller, Doris Rau, Susanne Mangold, Peter Kufer, Alexander Murr, Tobias Raum, Monika Wissinger
  • Patent number: 9695248
    Abstract: The invention includes stable multimeric, particularly dimeric, forms of PSMA protein, compositions and kits containing dimeric PSMA protein as well as methods of producing, purifying and using these compositions. Such methods include methods for eliciting or enhancing an immune response to cells expressing PSMA, including methods of producing antibodies to dimeric PSMA, as well as methods of treating cancer, such as prostate cancer.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: July 4, 2017
    Assignee: PSMA Development Company, LLC
    Inventors: Paul J. Maddon, Gerald P. Donovan, William C. Olson, Norbert Schuelke, Jason Gardner, Dangshe Ma
  • Patent number: 9694047
    Abstract: The use of autogenous bone graft is the current gold standard in the 1.5 million bone-grafting surgeries performed annually in the United States. Although this practice has resulted in high rates of fusion success, it is associated with increased operative time and blood loss, along with a significant degree of donor-site morbidity. Additionally, in certain settings such as revision cases, multilevel constructs, or in patients with medical co-morbidities, autogenous bone graft may exist in limited quantity and quality. This significant need for a suitable alternative to autogenous bone graft has stimulated great interest in the exploration of bone graft substitutes and extenders.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: July 4, 2017
    Assignee: The Regents of the University of California
    Inventors: Samuel S. Murray, Elsa J. Murray, Jeffrey Wang, Keyvan Behnam
  • Patent number: 9688738
    Abstract: The present invention describes methods and pharmaceutical compositions for the treatment of cancer in mammals, more particularly in human subjects. More specifically, the invention concerns anti-tumor vaccines based upon plasmid DNA and/or genetic vectors carrying a codon-usage optimized sequence and coding for a mutant form of the ErbB-3 receptor. Furthermore, the invention refers to monoclonal antibodies directed against the ErbB-3 receptor, obtained using these methods and capable to block its activity in cancer cells.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: June 27, 2017
    Assignee: TAKIS S.R.L.
    Inventors: Luigi Aurisicchio, Gennaro Ciliberto, Rita Mancini, Emanuele Marra, Guiseppe Roscilli
  • Patent number: 9689862
    Abstract: The present invention relates to an antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect, the invention relates to an antigen binding protein, or antigen binding fragments, capable of binding specifically to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding protein as an addressing product in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: June 27, 2017
    Assignee: PEIRRE FABRE MEDICAMENT
    Inventors: Charlotte Beau-Larvor, Liliane Goetsch, Nicolas Boute
  • Patent number: 9683039
    Abstract: The present invention is directed to methods of treating and preventing acute myeloid leukemia and acute myeloid leukemia relapse disease in a subject that involve administering a Notch receptor agonist.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 20, 2017
    Assignee: New York University
    Inventors: Iannis Aifantis, Camille Lobry
  • Patent number: 9683248
    Abstract: Nucleic acid sequences encoding chimeric polypeptides that exhibit enhanced cellulase activities are disclosed herein. These nucleic acids may be expressed in hosts such as fungi, which in turn may be cultured to produce chimeric polypeptides. Also disclosed are chimeric polypeptides and their use in the degradation of cellulosic materials.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: June 20, 2017
    Assignee: Alliance for Sustainable Energy, LLC
    Inventors: William S. Adney, Gregg T. Beckham, Eric Jarvis, Michael E. Himmel, Stephen R. Decker, Jeffrey G. Linger, Kara Podkaminer, John O. Baker, Larry Taylor, II, Qi Xu, Arjun Singh
  • Patent number: 9682122
    Abstract: The present invention relates to a method for the treatment of vascular dysfunction, reducing ischemic pain and/or treatment of a vascular disease comprising administering a therapeutically effective amount of Annexin A5 or a functional analog or variant thereof to a patient in need of such treatment. The vascular dysfunction, ischemic pain and/or vascular disease may be associated with impaired endothelium mediated vasodilatation, a reduced eNOS activity, and/or a reduced NO bioavailability. The patient may be suffering from a disease selected from angina pectoris, ischemic heart disease, peripheral artery disease, systolic hypertension, migraine, type 2 diabetes and erectile dysfunction.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: June 20, 2017
    Assignee: ANNEXIN PHARMACEUTICALS AB
    Inventors: Johan Frostegård, Knut Pettersson
  • Patent number: 9677138
    Abstract: A novel set of 98 genes expressed in the respiratory tract epithelium that serve as biomarkers for measuring chronic obstructive pulmonary disease (COPD) activity are provided. Methods of classifying the (COPD) status of a subject are provided. Systems for expression-based classification of COPD disease status are provided. Methods of treating COPD are also provided, among other things.
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: June 13, 2017
    Assignees: TRUSTEES OF BOSTON UNIVERSITY, THE BRITISH COLUMBIA CANCER AGENCY BRANCH
    Inventors: Katrina Steiling, Avrum Spira, Marc Lenberg, Stephen Lam
  • Patent number: 9676830
    Abstract: The present invention relates to chimeric GH61 polypeptides having cellulolytic enhancing activity. The present invention also relates to polynucleotides encoding the chimeric GH61 polypeptides; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the chimeric GH61 polypeptides.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: June 13, 2017
    Assignee: Novozymes, Inc.
    Inventors: Mark Wogulis, Matthew Sweeney, Tia Heu
  • Patent number: 9670255
    Abstract: It is an object of the present invention to provide a mutant streptavidin with a reduced affinity for natural biotin, and also to provide a modified biotin having a high affinity for the mutant streptavidin with a reduced affinity for natural biotin. According to the present invention, there is provided a reagent kit for use in treatments or diagnoses, which comprises: (a) a mutant streptavidin with a reduced affinity for natural biotin or biocytin; and a modified biotin having a high affinity for the above-described mutant streptavidin.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: June 6, 2017
    Assignee: SAVID THERAPEUTICS INC.
    Inventors: Akira Sugiyama, Hirofumi Doi, Tatsuhiko Kodama, Tsuyoshi Inoue, Eiichi Mizohata, Tatsuya Kawato, Tomohiro Meshizuka, Motomu Kanai, Yohei Shimizu, Tomohiro Yamamoto
  • Patent number: 9657101
    Abstract: The present invention provides reagents, methods and systems for predicting the inhibitory activity of an antibody or variant thereof comprising: determining a binding affinity of the antibody or variant thereof to a Fc activating receptor; determining a binding affinity of the antibody or variant thereof to a Fc inhibitory receptor, and calculating the ratio of said activating binding affinity to said inhibitory binding affinity (A/I ratio), wherein the magnitude of said ratio is less than one (1).
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: May 23, 2017
    Assignee: The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Rene G. Ott
  • Patent number: 9649355
    Abstract: The present invention relates to a method for the treatment of vascular dysfunction, reducing ischemic pain and/or treatment of a vascular disease comprising administering a therapeutically effective amount of Annexin A5 or a functional analog or variant thereof to a patient in need of such treatment. The vascular dysfunction, ischemic pain and/or vascular disease may be associated with impaired endothelium mediated vasodilatation, a reduced eNOS activity, and/or a reduced NO bioavailability. The patient may be suffering from a disease selected from angina pectoris, ischemic heart disease, peripheral artery disease, systolic hypertension, migraine, type 2 diabetes and erectile dysfunction.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: May 16, 2017
    Assignee: ANNEXIN PHARMACEUTICALS AB
    Inventors: Johan Frostegård, Knut Pettersson
  • Patent number: 9644013
    Abstract: A polypeptide capable of strongly inducing and activating dendritic-cell-like cells for treating or prevent cancer by immunotherapy, and DNA encoding the polypeptide. The polypeptide is a polypeptide (a) or (b) consisting of a partial region of the REIC/Dkk-3 protein.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: May 9, 2017
    Assignees: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY, MOMOTARO-GENE INC.
    Inventors: Hiromi Kumon, Masami Watanabe, Junichiro Futami, Yasuyuki Fujii, Hideo Ueki, Kazuhiko Ochiai
  • Patent number: 9642805
    Abstract: Disclosed herein is a nanoconstruct comprising an aptamer and a gold nanostar. The nanoconstruct can be used in a method of inducing changes to a nuclear phenotype of a cell comprising transporting the nanoconstruct to a nucleus of a cell, and releasing the aptamer from a surface of the gold nanostar into the nucleus of the cell to afford deformations or invaginations in the nuclear membrane, thereby inducing changes to the nuclear phenotype. The method can be used to treat certain hyperproliferative disorders such as cancer.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: May 9, 2017
    Assignee: Northwestern University
    Inventors: Teri W. Odom, Duncan-Hieu M. Dam, Jung Heon Lee
  • Patent number: 9637528
    Abstract: The invention provides directed evolution methods for improving the folding, solubility and stability (including thermostability) characteristics of polypeptides. In one aspect, the invention provides a method for generating folding and stability-enhanced variants of proteins, including but not limited to fluorescent proteins, chromophoric proteins and enzymes. In another aspect, the invention provides methods for generating thermostable variants of a target protein or polypeptide via an internal destabilization baiting strategy. Internally destabilization a protein of interest is achieved by inserting a heterologous, folding-destabilizing sequence (folding interference domain) within DNA encoding the protein of interest, evolving the protein sequences adjacent to the heterologous insertion to overcome the destabilization (using any number of mutagenesis methods), thereby creating a library of variants. The variants in the library are expressed, and those with enhanced folding characteristics selected.
    Type: Grant
    Filed: October 2, 2008
    Date of Patent: May 2, 2017
    Assignee: Los Alamos National Security, LLC
    Inventors: Andrew M. Bradbury, Csaba Kiss, Geoffrey S. Waldo
  • Patent number: 9636329
    Abstract: Disclosed herein are methods of treating, diagnosing, and prognosing GLUT-dependent cancers and OXPHOS-dependent cancers. In some embodiments, the methods comprise administering to a patient in need thereof a GLUT inhibitor and/or an OXPHOS inhibitor. The inhibitors may be administered before, concurrently, or after one another. Suitable GLUT-dependent cancers may include a GLUT4-dependent cancer, a GLUT8-dependent cancer, and a GLUT11-dependent cancer. Suitable GLUT inhibitors may include a GLUT4 inhibitor, a GLUT8 inhibitor, and a GLUT11 inhibitor. Suitable OXPHOS-dependent cancers may include mitochondrial OXPHOS-dependent cancers, including cancers that have developed resistance to treatment with a GLUT-inhibitor.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: May 2, 2017
    Assignee: Northwestern University
    Inventors: Malathy Shanmugam, Steven T. Rosen
  • Patent number: 9637749
    Abstract: Isolated mutant Mycobacterium tuberculosis bacteria comprising a deletion in the ESAT-6 gene cluster region 3 (esx-3 region) are provided, as well as compositions comprising such, methods of production thereof and methods of use thereof.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: May 2, 2017
    Assignee: Albert Einstein College of Medicine, Inc.
    Inventors: William R. Jacobs, JoAnn M. Tufariello
  • Patent number: 9603944
    Abstract: The present disclosure provides compositions and methods for efficient and effective protein delivery in vitro and in vivo. In some aspects, proteins are reversibly crosslinked to each other and/or modified with functional groups and protected from protease degradation by a polymer-based or silica-based nanoshell.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: March 28, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Li Tang, Darrell J. Irvine
  • Patent number: 9605083
    Abstract: Disclosed are specific binding agents such as antibodies and chimera that bind to JAM-like protein. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods related thereto.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: March 28, 2017
    Assignee: Emory University
    Inventors: Charles A. Parkos, Dominique A. Weber
  • Patent number: 9598512
    Abstract: Disclosed are an ultra-high molecular weight polyethylene resin for fiber and a preparation method thereof. The initial crystallinity of the resin is 60.5 to 90%, the volume average particle size is between 100 and 350 ?m, the particle-size distribution is 1.0-2.1, the molecular weight is 2-7 million, the tensile breaking stress is 30 to 60 MPa, the bulk density of the resin is 0.10 to 0.50 g/cm3, the infiltration time in the solvent decalin is 0.5 to 11 min, the decalin absorption amount of the resin is 2 to 50 g of decalin per 100 g of ultra-high molecular weight polyethylene resin, and the white oil absorption amount is 5 to 60 g of decalin per 100 g of ultra-high molecular weight polyethylene resin. The ethylene homopolymerization is performed using a slurry polymerization process in the presence of a main catalyst and a co-catalyst.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: March 21, 2017
    Assignee: CHINA PETROLEUM & CHEMICAL CORPORATION
    Inventors: Jianyong Zhou, Xiaoqing Li, Liuzhong Li, Xiaolong Bi, Wenyi Li, Yongling Yu
  • Patent number: 9592286
    Abstract: The present disclosure provides vaccine compositions comprising a PRRSV vaccine and a second porcine vaccine, which are substantially free from immuno-inhibition against each other. The second porcine virus vaccine can be CSFV and/or PRV. The preparation methods for the vaccines and the formulations are also provided. The vaccine compositions provided herein confer protective immunity to pigs against porcine reproductive and respiratory syndrome, classical swine fever, and/or pseudorabies.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: March 14, 2017
    Assignee: Sinovet (Beijing) Biotechnology Co., Ltd.
    Inventors: Hua Wu, Yanliang He, Mingqi Xia
  • Patent number: 9593018
    Abstract: Provided are a carbon nanotube composite containing a carbon nanotube coated with a protein having a catechol group and a metal ion bound to the catechol group and a method for manufacturing the same. According to the present disclosure, a carbon nanotube composite which exhibits controllable dispersibility and degree of crosslinkage while retaining the intrinsic physical properties of the carbon nanotube may be prepared. Since the phase change and tendency of aggregation of the carbon nanotube composite can be controlled quickly and repeatedly depending on the change in external environment, the carbon nanotube composite may be useful in various industrial fields including medicine, environment, etc. as a self-healing material.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: March 14, 2017
    Assignee: Korea Institute of Science and Technology
    Inventors: Yong Chae Jung, Sang Hyun Lee, Min Park
  • Patent number: 9587023
    Abstract: The invention relates to recombinant monovalent antibodies which are heterodimers of a first protein chain comprising the variable domain of the heavy chain of an antibody of interest and the CH2 and CH3 domains of an IgG immunoglobulin and a second protein chain comprising the variable domain of the light chain of said immunoglobulin of interest and the CH2 and CH3 domains of said IgG immunoglobulin. These antibodies can be used in particular as therapeutic agents in all cases where monovalent binding to a ligand such a cellular receptor is required.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: March 7, 2017
    Assignees: OSE Immunotherapeutics, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Bernard Vanhove, Caroline Mary, Flora Coulon
  • Patent number: 9578890
    Abstract: Methods are described for treating a whey protein mixture to increase a relative concentration of ?-lactalbumin protein in the mixture. The methods may include the step of adjusting a temperature of the whey protein mixture to about 10° C. or less, and adjusting the pH of the mixture to greater than 7. The may further include adding a protease enzyme to the whey protein mixture that selectively hydrolyzes ?-lactoglobulin protein in the mixture. The activity of the protease enzyme in the hydrolyzed whey protein mixture may be terminated before a substantial portion of the ?-lactalbumin protein has been hydrolyzed by the enzyme. In some instances, the whey protein mixture may also include glycomacropeptides that are selectively hydrolyzed with the ?-lactoglobulin protein. The ?-lactoglobulin and glycomacropeptide hydrolysates may be separated to produce an enhanced ?-lactalbumin protein composition for infant formula, among other products.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: February 28, 2017
    Assignee: Leprino Foods Company
    Inventors: Jiancai Li, Richard K. Merrill
  • Patent number: 9580513
    Abstract: We provide VHZ for use in a method of treatment, prophylaxis or alleviation of a cancer in an individual selected from the group consisting of: colon cancer, lung cancer, squamous cell carcinoma including lip, larynx, vulva, cervix and penis cancer, pancreatic cancer, brain cancer, oesophageal cancer, stomach cancer, bladder cancer, kidney cancer, skin cancer, ovary cancer, prostate cancer and testicular cancer. We provide an anti-VHZ agent for the treatment, prophylaxis or alleviation of such a cancer. The anti-VHZ agent may comprise SEQ ID NO:4 or SEQ ID NO: 5, or both.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: February 28, 2017
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR)
    Inventor: Qi Zeng
  • Patent number: 9572838
    Abstract: A method for production of anti-tumor TRAIL includes inserting a TRAIL molecule, encoded by a viral vector irreversibly derived from a cell line, into a carrier cell, thereby obtaining a stably TRAIL-producing carrier cell, and wherein the TRAIL molecule includes a soluble molecule.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: February 21, 2017
    Inventors: Massimo Dominici, Rita Bussolari, Giulia Grisendi, Pierfranco Conte
  • Patent number: 9575075
    Abstract: The present disclosure concerns a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected in the group comprising (i) a polypeptide comprising an amino acid sequence selected in the group comprising the amino acid sequence of the long isoform in Homo sapiens of the RdCVF2 gene (SEQ ID NO:10), orthologs, derivatives and fragments thereof, (ii) a polynucleotide coding for said polypeptide, (iii) a vector comprising said polynucleotide, and (iv) a host cell genetically engineered expressing said polypeptide; the use of such a composition for the manufacture of a medicament for treating and/or preventing a neurodegenerative disorder in a subject; and a method of testing a subject thought to have or be predisposed to having a neurodegenerative disorder.
    Type: Grant
    Filed: June 5, 2008
    Date of Patent: February 21, 2017
    Assignees: INSERM (Institut National de la Sante et Recherche Medicale), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Thierry Leveillard, José-Alain Sahel, Céline Jaillard, Olivier Poch
  • Patent number: 9567374
    Abstract: The present invention proposes a method for generating cyan fluorescent proteins which have reduced pH sensitivity, in particular acid-pH sensitivity.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: February 14, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERWSITE PARIS-SUD 11
    Inventors: Hélène Pasquier, Fabienne Merola, Marie Erard, Agathe Espagne, Asma Fredj
  • Patent number: 9562091
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: February 7, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Fiona Grueninger, Guy Georges, Olaf Mundigl, Michael Schraeml, Bernd Bohrmann, Ulrich Goepfert, Joerg Benz, Hubert Kettenberger
  • Patent number: 9555087
    Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants awhich are suitable targets for immunotherapy, cancer therapy, and drug development.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: January 31, 2017
    Assignee: COMPUGEN LTD
    Inventors: Amir Toporik, Amit Novik, Anat Cohen-Dayag, Avi Yeshah Rosenberg, Cynthia Koifman, Dalit Landesman-Milo, Eve Montia, Galit Rotman, Liat Dassa, Marina Bubis, Merav Beiman, Ofer Levi, Sergey Nemzer, Tania Pergam, Yaron Kinar, Shirley Sameach- Greenwald, Zurit Levine, Shira Walach
  • Patent number: 9533027
    Abstract: Compositions of matter and methods for making, storing and administering artificial blood substitutes. Artificial blood substitutes may have oxygen carriers that encapsulate an oxygen-binding compound in a polymer vesicle. Oxygen-binding compounds may include hemoglobin, myoglobin, or other oxygen binding compounds having characteristics similar to hemoglobin. Oxygen carriers may include nanoparticles, polymers and/or polymersomes comprising of poly(ethylene oxide)-block-poly(?-caprolactone) (PEO-b-PCL) and related diblock copolymers of poly(ethylene oxide)-block-poly(?-methyl ?-caprolactone) (PEO-b-PMCL). The oxygen carriers may have tunable oxygen-binding capacities, uniform and appropriately small size distributions, and human bloodlike viscosities and oncotic properties.
    Type: Grant
    Filed: July 24, 2014
    Date of Patent: January 3, 2017
    Assignee: Vindico NanoBioTechnology, LLC
    Inventors: P. Peter Ghoroghchian, Eric Ostertag
  • Patent number: 9534028
    Abstract: The present invention relates to a method for the preparation of a concentrate of serum proteins with reduced lactose content from a sample of lactoserum, wherein said concentrate is characterized in that it comprises a concentration of 0.5 grams of lactose per kilogram of protein, the concentrate obtainable from said process and food products containing said concentrate.
    Type: Grant
    Filed: August 13, 2013
    Date of Patent: January 3, 2017
    Assignee: LB LYOPHARM S.R.L.
    Inventor: Christian Rebière
  • Patent number: 9533035
    Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.
    Type: Grant
    Filed: May 29, 2008
    Date of Patent: January 3, 2017
    Assignees: XIAMEN UNIVERSITY, BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.
    Inventors: Jun Zhang, Jin Wang, Chunyan Yang, Ying Gu, Shaowei Li, Ningshao Xia